Delving into the Latest Updates on SAL-0140 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

SAL 0140, SAL0140

Target

Aldosterone

Action

antagonists

Mechanism

Aldosterone antagonists

Therapeutic Areas

Cardiovascular DiseasesUrogenital Diseases

Active Indication

HypertensionChronic Kidney Diseases

Inactive Indication-

Originator Organization

Shenzhen Salubris Pharmaceuticals Co., Ltd.

Active Organization

Shenzhen Salubris Pharmaceuticals Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：评价 SAL0140 片在中国成年健康研究参与者中单次和多次给药的安全性和耐受性。次要目的：评价 SAL0140 片在中国成年健康研究参与者中单次和多次给药的药代动力学特征；评价 SAL0140 片在中国成年健康研究参与者中单次和多次给药的药效学特征[药效学指标包括血浆醛固酮、尿液醛固酮等]；初步评价食物对 SAL0140 片在中国成年健康研究参与者中药代动力学特征的影响；通过 C-QTc 模型化分析，评价 SAL0140 对 QT 间期的影响。

[Translation]

Primary objective: To evaluate the safety and tolerability of single and multiple doses of SAL0140 tablets in Chinese adult healthy study participants. Secondary objectives: To evaluate the pharmacokinetic characteristics of single and multiple doses of SAL0140 tablets in Chinese adult healthy study participants; To evaluate the pharmacodynamic characteristics of single and multiple doses of SAL0140 tablets in Chinese adult healthy study participants [pharmacodynamic indicators include plasma aldosterone, urine aldosterone, etc.]; To preliminarily evaluate the effect of food on the pharmacokinetic characteristics of SAL0140 tablets in Chinese adult healthy study participants; To evaluate the effect of SAL0140 on the QT interval through C-QTc modeling analysis.

Start Date-

Sponsor / Collaborator

Shenzhen Salubris Pharmaceuticals Co., Ltd.

100 Clinical Results associated with SAL-0140

Login to view more data

100 Translational Medicine associated with SAL-0140

Login to view more data

100 Patents (Medical) associated with SAL-0140

Login to view more data

100 Deals associated with SAL-0140

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hypertension	Phase 1	China	Shenzhen Salubris Pharmaceuticals Co., Ltd.	23 May 2025
Chronic Kidney Diseases	Preclinical	China	Shenzhen Salubris Pharmaceuticals Co., Ltd.	27 Aug 2024